全文获取类型
收费全文 | 1701篇 |
免费 | 137篇 |
国内免费 | 3篇 |
专业分类
耳鼻咽喉 | 27篇 |
儿科学 | 22篇 |
妇产科学 | 22篇 |
基础医学 | 268篇 |
口腔科学 | 16篇 |
临床医学 | 202篇 |
内科学 | 285篇 |
皮肤病学 | 21篇 |
神经病学 | 111篇 |
特种医学 | 98篇 |
外科学 | 277篇 |
综合类 | 12篇 |
预防医学 | 133篇 |
眼科学 | 30篇 |
药学 | 116篇 |
中国医学 | 7篇 |
肿瘤学 | 194篇 |
出版年
2024年 | 3篇 |
2023年 | 22篇 |
2022年 | 46篇 |
2021年 | 88篇 |
2020年 | 36篇 |
2019年 | 67篇 |
2018年 | 65篇 |
2017年 | 40篇 |
2016年 | 40篇 |
2015年 | 51篇 |
2014年 | 66篇 |
2013年 | 85篇 |
2012年 | 126篇 |
2011年 | 114篇 |
2010年 | 58篇 |
2009年 | 67篇 |
2008年 | 84篇 |
2007年 | 102篇 |
2006年 | 81篇 |
2005年 | 82篇 |
2004年 | 79篇 |
2003年 | 61篇 |
2002年 | 52篇 |
2001年 | 44篇 |
2000年 | 35篇 |
1999年 | 41篇 |
1998年 | 11篇 |
1997年 | 14篇 |
1996年 | 13篇 |
1995年 | 11篇 |
1994年 | 3篇 |
1993年 | 4篇 |
1992年 | 20篇 |
1991年 | 14篇 |
1990年 | 18篇 |
1989年 | 17篇 |
1988年 | 21篇 |
1987年 | 5篇 |
1986年 | 11篇 |
1985年 | 5篇 |
1984年 | 5篇 |
1981年 | 2篇 |
1979年 | 2篇 |
1974年 | 4篇 |
1972年 | 4篇 |
1971年 | 4篇 |
1970年 | 4篇 |
1969年 | 4篇 |
1968年 | 3篇 |
1967年 | 2篇 |
排序方式: 共有1841条查询结果,搜索用时 13 毫秒
31.
Diagnostic value of biparametric magnetic resonance imaging (MRI) as an adjunct to prostate‐specific antigen (PSA)‐based detection of prostate cancer in men without prior biopsies 下载免费PDF全文
Soroush Rais‐Bahrami M. Minhaj Siddiqui Srinivas Vourganti Baris Turkbey Ardeshir R. Rastinehad Lambros Stamatakis Hong Truong Annerleim Walton‐Diaz Anthony N. Hoang Jeffrey W. Nix Maria J. Merino Bradford J. Wood Richard M. Simon Peter L. Choyke Peter A. Pinto 《BJU international》2015,115(3):381-388
32.
33.
34.
35.
36.
Robert A. Hauser Daniel Truong Jean Hubble Chandra Coleman Jean-Luc Beffy Stephen Chang Philippe Picaut 《Journal of neural transmission (Vienna, Austria : 1996)》2013,120(2):299-307
Treatment with botulinum toxin-A is recommended as first-line treatment for cervical dystonia (CD). In clinical practice many factors appear to influence dose adjustment and the retreatment regimen; however, there is little information available in the literature regarding the evolution of dosing over treatment cycles. We report on two similarly designed, long-term, multicenter, open-label extension studies of Dysport for the treatment of CD, which followed 500 U fixed-dose placebo-controlled trials. Both studies specified a fixed 500 U dose for the first open-label treatment cycle, with dose adjustment in subsequent treatment cycles according to the clinical response. These analyses include 218 patients who entered the two studies; doses in the subsequent treatment cycles ranged between 250 and 1,000 U. During open-label treatment, all treatment cycles resulted in improvements in mean Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) total scores. However, increasing the dose of Dysport above the initial 500 U dose was not observed to result in an incremental improvement in response as measured by the TWSTRS. No individual patient characteristic was found to reliably predict the use of higher doses at each treatment cycle. Dysport was generally well tolerated with no major differences in the incidence of adverse events (AEs) observed with different doses. Dysphagia was considered an AE of special interest and dysphagia data from the open-label studies were combined with two Phase II studies. Analysis of this enhanced database indicates that unilateral injections of >150 U into the sternocleidomastoid muscle is associated with a higher dysphagia risk. Thus, limiting the dose in the sternocleidomastoid may help reduce the incidence of dysphagia. 相似文献
37.
38.
39.
40.